WillItSurvive
Pharma and healthcare groups · China

Jiangsu Hengrui Pharmaceuticals

hengrui.com ↗

China's largest listed drugmaker, oncology-heavy, licensing pipeline drugs to Western pharma majors.

Defensible for now
Assessed 25 July 2026 · Evidence as of 25 July 2026
Real protection, with named pressure against it.
On the recordSince 25 July 2026 · Checkable from Jul 2026 · Every call on the record Checkpoint: FDA decision on camrelizumab-rivoceranib after third CRL tied to manufacturing
The call

Hengrui's China regulatory and manufacturing position still holds, but a pattern of FDA quality issues sits under the licensing deals that now drive its growth story.

Hengrui makes and sells pharmaceuticals, mostly in China, where it has built advantages that are hard for foreign competitors to copy, like regulatory approvals and relationships with Chinese hospitals. American and European drug companies are instead buying the rights to Hengrui's drugs rather than trying to compete directly. The company's recent growth story depends heavily on payments it might receive from those deals in the future, not money it has already earned, and Hengrui has had repeated trouble passing U.S. factory inspections, which could make international partners nervous and shrink the deal pipeline that investors are betting on.

Why
01
AI pressure: Insilico Medicine and AI-native drug discovery platforms. AI-native labs compete for early discovery deals upstream, but can't touch Hengrui's NMPA approvals or GMP plants. Could AI do the core job? Unlikely.
02
Bigger players: BeiGene, Innovent Biologics, Junshi, Akeso, and Hansoh. Domestic rivals run the same China-to-West licensing playbook, competing for the same partners and NRDL slots. Could a giant copy it? No, they are blocked.
03
What protects it. NMPA approval history, NRDL reimbursement access, deep China trial data, and GMP-certified manufacturing scale.
What would change this call
Whether a GMP manufacturing deficiency recurs on a second Hengrui product or a GSK/BMS/Merck-licensed asset. Would show the FDA quality issue is systemic, threatening partner confidence in the licensing pipeline.
GSK's decisions on exercising options for the 11 additional licensed programs over the next 1-3 years. Shows whether a major partner still values Hengrui's pipeline enough to pay milestone fees.
Kailera's Phase 3 obesity trial readouts for ribupatide (oral and injectable) in 2026-2027. Determines whether Hengrui's 19.9% Kailera equity stake converts into real value.
Key numbers
  • FY2025 revenue RMB31.63bn, up 13% YoY (2025-12-31)
  • GSK deal: up to $12.5bn potential, $500M upfront (2025-07-28)
  • HKEX IPO raised HK$9.9bn, shares up 29% on debut (2025-05-23)
Named risks
  • Three FDA CRLs on same product plus 2024 warning letter suggest systemic GMP quality issue. Severity: high
  • Growth narrative leans on contingent milestone-based deal value (est. $40bn) rather than banked cash. Severity: medium
  • Crowded domestic field (BeiGene, Innovent, Akeso, Hansoh) runs identical license-out model, pressuring differentiation. Severity: medium
  • GSK's 11 option programs depend on Phase I completion and option exercise over 1-3 years, could shrink headline value. Severity: medium
  • China NRDL reimbursement price negotiations could compress margins on newly listed drugs. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
BeiGenecontestingRuns same license-out/global commercial model with PD-1 Tevimbra, as of 2026
Innovent BiologicscontestingDomestic peer partnered with Eli Lilly, competing in same oncology licensing space
Novo Nordisk and Eli LillycontestingDominate global obesity market Hengrui enters via Kailera's GLP-1 pipeline, 2026 Phase 3 readouts pending
Insilico Medicinegaining onAI-native drug discovery platform Pharma.AI IPO'd Dec 2025, different model upstream of Hengrui
AkesocontestingDomestic bispecific/ADC rival running similar out-licensing playbook as of 2025-2026
Questions people ask
Is Jiangsu Hengrui Pharmaceuticals profitable?
Yes. Hengrui reported FY2025 net profit attributable to shareholders of RMB 7.72 billion, up 21.8% year over year, on revenue of RMB 31.63 billion, as disclosed in its March 25, 2026 annual results announcement.
Could AI replace Hengrui's drug discovery work?
Unlikely to replace it entirely. Hengrui has used Iktos's generative AI tool Makya for hit-to-lead work since December 2021, but its moat rests on NMPA regulatory approvals, GMP manufacturing, and proprietary Chinese clinical data that AI models cannot replicate.
Who is Hengrui's biggest competitor?
Domestically, BeiGene, Innovent Biologics, Junshi Biosciences, Akeso and Hansoh run the same innovative-drug-plus-out-licensing model. Globally, Novo Nordisk and Eli Lilly dominate the obesity market Hengrui is entering via its Kailera Therapeutics stake as of 2026.
Who owns Jiangsu Hengrui Pharmaceuticals?
Hengrui is an independent, publicly traded company with no single parent, dual-listed on the Shanghai Stock Exchange (600276.SH since 2000) and Hong Kong Stock Exchange (1276.HK since May 23, 2025). Chairman is Sun Piaoyang.
What is driving Hengrui's recent growth?
Out-licensing deals to Western pharma are central: GSK (up to $12.5bn potential, July 2025), Bristol Myers Squibb (up to $15.2bn, May 2026), Merck (HRS-5346, March 2025) and Kailera Therapeutics, alongside FY2025 revenue of RMB 31.63bn.
Has Jiangsu Hengrui had FDA problems?
Yes. The FDA issued a warning letter to Hengrui's Huanghe Road plant in July 2024 and, in July 2026, rejected the camrelizumab-rivoceranib liver cancer combination for a third time over cGMP manufacturing deficiencies at a Hengrui facility.
Timeline
  • 2026-07-10FDA issues third CRL for camrelizumab-rivoceranib over manufacturing deficiencies
  • 2026-06-30NMPA approves Heng Yi ophthalmic solution with partner Novaliq
  • 2026-05-15Bristol Myers Squibb alliance for 13 programs, up to $15.2bn potential
  • 2026-04Kailera Therapeutics, built on Hengrui-licensed GLP-1 assets, IPOs on Nasdaq
  • 2026-03-25FY2025 results: RMB 31.63bn revenue, RMB 7.72bn net profit
  • 2025-12-07Four Hengrui drugs added to China's NRDL effective Jan 1, 2026
  • 2025-09-05License HRS-1893 to Braveheart Bio outside Greater China
  • 2025-07-28GSK collaboration signed, up to 12 programs, up to $12.5bn potential
  • 2025-05-23Hong Kong Stock Exchange debut, shares jump 29%, raises HK$9.9bn
  • 2025-03-25Merck (MSD) licenses HRS-5346 Lp(a) inhibitor for $200M upfront
Head to head
Fosun Pharma vs Jiangsu Hengrui Pharmaceuticals
Revision history
25 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
ZoetisBoston ScientificBecton Dickinson
More in Pharma and healthcare groups →
Sources